Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Liabilities and Shareholders Equity: 2013-2024

Historic Liabilities and Shareholders Equity for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $144.2 million.

  • Fortress Biotech's Liabilities and Shareholders Equity rose 42.74% to $181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.6 million, marking a year-over-year increase of 9.70%. This contributed to the annual value of $144.2 million for FY2024, which is 13.91% down from last year.
  • Fortress Biotech's Liabilities and Shareholders Equity amounted to $144.2 million in FY2024, which was down 13.91% from $167.5 million recorded in FY2023.
  • Fortress Biotech's 5-year Liabilities and Shareholders Equity high stood at $396.5 million for FY2021, and its period low was $144.2 million during FY2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $167.5 million (2023), whereas its average is $202.0 million.
  • Per our database at Business Quant, Fortress Biotech's Liabilities and Shareholders Equity surged by 47.25% in 2020 and then plummeted by 43.08% in 2023.
  • Over the past 5 years, Fortress Biotech's Liabilities and Shareholders Equity (Yearly) stood at $333.4 million in 2020, then increased by 18.92% to $396.5 million in 2021, then dropped by 25.78% to $294.3 million in 2022, then plummeted by 43.08% to $167.5 million in 2023, then decreased by 13.91% to $144.2 million in 2024.